Advertisement

A part of Watch Medier

MedWatch
  • Latest
  • Search
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Buy
MedWatch
  • Search
  • Log in
  • Buy
MedWatch

Sections

  • Latest news
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other

About MedWatch

  • Contact the editorial team
  • Our values
  • About MedWatch
  • Follow us on LinkedIn
  • Available jobs in the industry

Get access

  • Log in
  • Buy subscription
  • Subscribe to newsletters
  • Contact customer service

Apps

  • Download app for iOS
  • Download app for Android
2026 © MedWatch
A part of Watch Medier
According to Lundbeck, the company is “not on track” when it comes to achieving its goal of reducing its CO2 emissions by 90% in 2050. | Foto: Jens Dresling
StrategySubscription

Lundbeck falls short of 2025 climate targets

  • Lundbeck CEO received a small pay rise in 2025

  • Lundbeck expects revenue growth of 5-8% in 2026

Coloplast is still searching for a new CEO. Until the right candidate is found, Lars Rasmussen will remain at the helm of the Danish medical device company. | Foto: Thomas Emil Sørensen
MedtechSubscription

Coloplast off to weak start, misses growth and earnings expectations

"The FDA cannot verify the quality, safety, or efficacy of unapproved drugs," writes FDA Commissioner Marty Makary on social media platform X. | Foto: Kevin Lamarque
Pharma & biotechSubscription

FDA warns compounders after reports of Wegovy tablet knockoffs

You’re going to see numbers that you’re not going to believe,” Trump said at the press conference last night. | Foto: Al Drago
Pharma & biotechSubscription

Trump lowers Wegovy price on new website

Senior Analyst at Sydbank, Søren Løntoft Hansen. | Foto: Sydbank
MedtechSubscription

Coloplast stock may suffer from weak start to the year, says analyst

Novo Nordisk is just shy of several diversity targets that were to be achieved by the end of 2025. | Foto: Tom Little
Pharma & biotechSubscription

Novo Nordisk fails to hit all diversity targets for 2025

Søren Jelert, Chief Financial Officer at GN | Foto: Gn / Pr
Hearing healthSubscription

GN CFO: Stake sale could help reduce towering debt

Jobs

Image

Information Security Advisor

Image

Global Safety Lead, Global Medical Safety

Image

Programme Fellow - BioSustainability Design Novo Nordisk Foundation Fellowship Programme (BSD)

See all jobs
Foto: Thomas Lekfeldt
Hearing healthSubscription

GN takes a beating during teleconference with analysts

Søren Nielsen, CEO of Demant, is to cut 700 jobs as part of a major cost-cutting plan. | Foto: Kenneth Lysbjerg Koustrup
Did you read?Subscription

Major layoffs hit the Demant organization hard

Novo Nordisk will ”initiate legal and regulatory actions” against Hims and Hers. | Foto: Tom Little
Pharma & biotechSubscription

Novo Nordisk takes legal action against Hims and Hers

Novo Nordisk launched its Wegovy tablet at the beginning of the year. | Foto: Novo Nordisk / Pr
Pharma & biotechSubscription

Hims & Hers will sell copies of the Wegovy pill for USD 49

The stock of Hims and Hers was high on Thursday but has since fallen to its lowest level since 2024. | Foto: Tom Little
Pharma & biotechSubscription

Hims and Hers turns negative after threat from Novo Nordisk

The copy product from Hims and Hers is a waste of money, according to Novo Nordisk's CEO, Mike Doustdar. | Foto: Peter Maunsbach
Pharma & biotechSubscription

Doustdar doubts effect of copy pill: "Waste of 49 dollars"

The former female employee who initiated legal proceedings against Novo Nordisk ultimately had to take sick leave as a result of her experiences at the pharmaceutical company. | Foto: Finn Frandsen
Did you read?Subscription

"Belittled" and "threatened" every week: Former employee accuses Novo Nordisk in the US of sexist culture

A revision of European pharmaceutical legislation is now in place after the European Parliament and the Council reached an agreement last night on a comprehensive revision of the rules in this area. | Foto: Gonzalo Fuentes

Industry passes judgment on new drug regulation: Better than feared, but a blow to Europe's competitiveness

Read the article here
EU lands major pharmaceutical package
“A step in the wrong direction:" Industry fears consequences of new EU pharma package
The final sprint on the pharmaceutical package is underway: The battle of new medicines' protection in the EU
Mike Doustdar was appointed CEO of Novo Nordisk in 2025. | Foto: Thomas Traasdahl
Pharma & biotechSubscription

Novo investors' confidence under pressure: “There is no room for further disappointments”

Peter Karlstromer is the CEO of GN. | Foto: Gn / Pr
Hearing healthSubscription

GN notes positive winds in the US after tough year – plans to launch new top product in 2026

Novo Nordisk CEO Mike Doustdar (left) and CFO Karsten Munk Knudsen are being overtaken by competitor Eli Lilly in the GLP-1 market based on sales of the companies’ most important drugs. | Foto: Thomas Traasdahl
Pharma & biotechSubscription

Eli Lilly surpassed Novo Nordisk in key GLP-1 market in 2025

Most read

1

FDA warns compounders after reports of Wegovy tablet knockoffs

2

Major layoffs hit the Demant organization hard

3

"Belittled" and "threatened" every week: Former employee accuses Novo Nordisk in the US of sexist culture

4

Retail now accounts for most of Demant's revenue

5

Demant to cut 700 jobs in major cost-saving initiative

Boston Scientific competes with both Danish companies Coloplast and Ambu. | Foto: Clodagh Kilcoyne
MedtechSubscription

Boston Scientific disappoints with low forecast for 2026

Lundbeck, headed by CEO Charl van Zyl, had a good year in 2025 with record revenue of DKK 24.6bn. | Foto: Thomas Lekfeldt
Pharma & biotechSubscription

Lundbeck continues acquisition hunt after Avadel defeat

Coloplast is expected to report its financial results for the first quarter of the staggered fiscal year 2025/26 on Friday morning. | Foto: Coloplast / PR
MedtechSubscription

Analysts expect a subdued start to the year for Coloplast: Challenges in China will continue to weigh heavily

Debt-ridden GN reduced its debt by DKK 800m during 2025. | Foto: Thomas Lekfeldt
Hearing healthSubscription

GN cuts debt further as dividend remains on hold

Charl van Zyl became CEO of Lundbeck in 2023. | Foto: Magnus Møller
Pharma & biotechSubscription

Lundbeck CEO received a small pay rise in 2025

Foto: Hollie Adams
Pharma & biotechSubscription

11 patients awarded compensation over eye disease linked to Novo products

On Sunday, February 8, the Super Bowl will be held in California, where Novo Nordisk will advertise the new Wegovy tablet. | Foto: Carlos Barria
Pharma & biotechSubscription

Novo Nordisk to promote Wegovy at Super Bowl as part of intensified marketing focus

Charl van Zyl is confident despite increased price pressure and competition for the best-selling Rexulti. | Foto: Thomas Lekfeldt
Pharma & biotechSubscription

Lundbeck CEO on crucial price negotiations for blockbuster drug in the US: “We are prepared”

Britt Meelby Jensen has been CEO of Ambu since 2022. | Foto: PR/Ambu
MedtechSubscription

Ambu CEO confident in growth targets despite tough conditions from tariffs and FX

As CEO of Novo Nordisk, Mike Doustdar is confident about the company's economies of scale in competition with smaller copycats.
StrategySubscription

Novo Nordisk CEO on new price pressure risk: We have economies of scale

Foto: Thomas Lekfeldt
Hearing healthSubscription

GN's hearing aid activities achieved organic growth of 5% in 2025

Lundbeck CEO Charl van Zyl has several candidates in the pipeline who are crucial to the company's future success. | Foto: Magnus Møller
Pharma & biotechSubscription

Lundbeck CEO predicts results for migraine candidate as next major catalyst

Jobs

Image

Pharmacokineticist, PK/PD Modelling & Simulation

Image

Head of Sales Batch Freeze Dryer Food, GEA Process Engineering

Image

Senior or Principal Analytical Scientist

See all jobs

Colophon

MedWatch

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • RSS feeds

Follow us on

Editor

Ulrich Quistgaard

uq@medwatch.dk

Tel.: +45 3330 8349

Read about the editorial team

Press Releases

medwatch@medwatch.dk

Debate

medwatch@medwatch.dk

We take responsibility for the content and are signed up to Pressenævnet

Editorial guidelines

  • Review of quotes by sources
  • Use of AI
  • Employee stock investments

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 70 77 71 25

Buy subscription
Company subscription

Job Advertising

job@infowatch.dk

Tel.: +45 70 77 71 25

Read more about jobs

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7125

Read more about banners

Support

Contact customer service

About MedWatch

MedWatch is a part of Watch Medier.

Read more about MedWatch

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Editor-in-chief

Rasmus Emborg

Publisher

JP/Politiken Media Group Ltd

Terms and consent

  • Cookie policy
  • Privacy policy

Copyright © MedWatch — All rights reserved

  • Pharma & biotech

    FDA warns compounders after reports of Wegovy tablet knockoffs

  • Strategy

    Lundbeck falls short of 2025 climate targets

  • Medtech

    Coloplast off to weak start, misses growth and earnings expectations

  • Pharma & biotech

    Trump lowers Wegovy price on new website

  • Medtech

    Coloplast stock may suffer from weak start to the year, says analyst

  • Hearing health

    GN CFO: Stake sale could help reduce towering debt

  • Pharma & biotech

    Novo Nordisk fails to hit all diversity targets for 2025

  • Hearing health

    GN takes a beating during teleconference with analysts

  • Pharma & biotech

    Hims & Hers will sell copies of the Wegovy pill for USD 49

  • Pharma & biotech

    Hims and Hers turns negative after threat from Novo Nordisk

  • More news
More news

Jobs

Image

Information Security Advisor

Image

Global Safety Lead, Global Medical Safety

Image

Programme Fellow - BioSustainability Design Novo Nordisk Foundation Fellowship Programme (BSD)

Image

Pharmacokineticist, PK/PD Modelling & Simulation

Image

Head of Sales Batch Freeze Dryer Food, GEA Process Engineering

Image

Senior or Principal Analytical Scientist

See all jobs

MedWatch

Investeringsøkonom: Novo Nordisk skal stadig vinde flere slag
Hims & Hers dropper kopi af Novo Nordisks vægttabspille få dage efter lancering
FDA vil gå i kødet på kopister inden for fedmemedicin
Iagttagere stiller flere spørgsmål ved Hims and Hers kopiprodukt

MedWatch

Beslutningsforum skal ta stilling til celleterapi og subkutan Keytruda
Sensocure lanserer sensor i Norge som første marked
EPJ-oversikten: Milliarder ute på anbud: – Jeg lurer på om det har gått litt for fort
GE Healthcare rigger om for å unngå tollsmell

KapitalWatch

ATP's afkast voksede i årets tre sidste måneder
Frank Hvids klumme: Svage jobtal skaber tvivl om styrken af amerikansk økonomi
Selskaber trækker i bremsen: Udsættelser præger Eifos milliardstøtte til vind og PTX
Tidligere DSV-speditør vil rejse kapital til ny fragtplatform

AdvokatWatch

Fynsk advokatfirma vil bevare Ærø-kontor trods partnerexit
Ugens bedste historier på AdvokatWatch
Domstolsstyrelsens direktør bliver partner i PWC
Advokat i ny rolle ser frem til globalt arbejde med ejendomme
Advertisement